JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB313064

重组Alexa Fluor® 568荧光Anti-VEGF Receptor 1抗体[Y103]

Alexa Fluor® 568 Anti-VEGF Receptor 1 antibody [Y103]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal VEGF Receptor 1 antibody - conjugated to Alexa Fluor® 568.

查看别名

FLT, FRT, VEGFR1, FLT1, Vascular endothelial growth factor receptor 1, VEGFR-1, Fms-like tyrosine kinase 1, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor, FLT-1

不同偶联物与剂型 (7)

关键信息

宿主种属

Rabbit

克隆

Monoclonal

克隆号

Y103

亚型

IgG

偶联物

Alexa Fluor® 568

激发波长/发射波长

Ex: 578nm, Em: 603nm

不含载体蛋白

No

应用

Antibody Labelling, Target Binding Affinity

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

特异性

Based on the antibody's immunogen sequence, it recognises 151 kDa VEGF receptor 1/Flt1, splice isoforms sFlt1 (77 kDa) and sFlt1-14 (82 kDa), and isoform 4 (61 kDa). The sequence is not present in isoforms 5-8 based on Uniprot ID P17948.

您可能对以下产品感兴趣:

AB289705

Human VEGF R1 (FLT1) ELISA Kit

0

0 Reviews

查看产品
为什么推荐这个?

我们推荐这个产品,因为它经常被用于相同的实验或相关的研究。

我们建议您务必查阅产品说明书,以确认其是否符合您的实验需求;若有疑问,也可联系我们的技术团队获取协助。

产品详情

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification Protein A
存储溶液
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
运输条件
Blue Ice
推荐的短期储存时间
1-2 weeks
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle|Store in the dark

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

VEGF Receptor 1 also known as FLT-1 is a protein that plays a critical role in the regulation of angiogenesis. Its mass is approximately 180 kDa. FLT-1 is a receptor tyrosine kinase expressed mainly on the surface of endothelial cells but also in monocytes and macrophages. The receptor binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) which initiates a series of signaling cascades important for vascular development and function.
Biological function summary

FLT-1 mediates important cellular responses such as cell migration and proliferation. Although it often functions in conjunction with other receptors like VEGFR-2 FLT-1 has unique binding affinities that modulate the availability of VEGF for other receptors. FLT-1 proteins as part of complex signaling networks actively contribute to maintaining vascular homeostasis and regulating blood vessel permeability.

Pathways

FLT-1 is an important component in the VEGF signaling pathway and also part of the PlGF/VEGF pathway. The receptor serves as a decoy to regulate the amount of VEGF interaction with VEGFR-2 influencing endothelial cell function and vascular permeability. By sequestering VEGF FLT-1 helps maintain the balance in this angiogenic signaling network interacting with proteins like VEGF PlGF and the anti-VEGF agents that target these pathways.

FLT-1 is implicated in cancer and diabetic retinopathy. Overexpression or dysregulation of FLT-1 can contribute to tumor angiogenesis which can enhance tumor growth and metastasis. In diabetic retinopathy abnormal FLT-1 activity affects retinal blood vessels leading to vision impairment. Similar interactions involve VEGFR-2 and other downstream effectors emphasizing the potential of FLT-1 as a therapeutic target for conditions associated with excessive angiogenesis and vascular dysfunction.

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

靶点信息

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. Acts as a positive regulator of postnatal retinal hyaloid vessel regression (By similarity). May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1 (PubMed : 16685275).. Isoform 1. Phosphorylates PLCG.. Isoform 2. May function as decoy receptor for VEGFA.. Isoform 3. May function as decoy receptor for VEGFA.. Isoform 4. May function as decoy receptor for VEGFA.. Isoform 7. Has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion.
See full target information FLT1

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com